ES2150107T3 - Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. - Google Patents

Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Info

Publication number
ES2150107T3
ES2150107T3 ES96906795T ES96906795T ES2150107T3 ES 2150107 T3 ES2150107 T3 ES 2150107T3 ES 96906795 T ES96906795 T ES 96906795T ES 96906795 T ES96906795 T ES 96906795T ES 2150107 T3 ES2150107 T3 ES 2150107T3
Authority
ES
Spain
Prior art keywords
directed against
antibodies directed
immunogenes
immunogens
retroviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96906795T
Other languages
English (en)
Other versions
ES2150107T5 (es
Inventor
Jean-Francois Zagury
Bernard Bizzini
Daniel Zagury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neovacs SA
Original Assignee
Neovacs SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs SA filed Critical Neovacs SA
Publication of ES2150107T3 publication Critical patent/ES2150107T3/es
Application granted granted Critical
Publication of ES2150107T5 publication Critical patent/ES2150107T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1147—Regulatory proteins, e.g. trans-activator of transcription [TAT], rev or vacuolar protein targeting [VPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTO INMUNOGENO ADMINISTRABLE AL HOMBRE YA QUE ESTA DESPROVISTO DE TOXICIDAD, QUE SE DERIVA DE UNA PROTEINA DE REGULACION DE UN VIRUS VIH TRATAMIENTO QUIMICO MEDIANTE UN AGENTE DE ACOPLAMIENTO TAL COMO UN ALDEHIDO, O DE UNA PROTEINA PORTADORA ACTIVADA POR UN PRETRATAMIENTO MEDIANTE UN ALDEHIDO, QUE LE PERMITE SER RECONOCIDO POR ANTICUERPOS DIRIGIDOS CONTRA DICHA PROTEINA DE REGULACION, Y CONSERVAR PROPIEDADES INMUNOGENAS SUFICIENTES PARA CREAR ANTICUERPOS QUE NEUTRALIZAN O BLOQUEAN DICHA PROTEINA NATIVA, A LA VEZ QUE SE PIERDEN AL MENOS 50 % DE LAS PROPIEDADES BIOLOGICAS TOXICAS DE DICHA PROTEINA NATIVA.
ES96906795T 1995-03-08 1996-03-07 Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen. Expired - Lifetime ES2150107T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9502708 1995-03-08
FR9502708A FR2731355B1 (fr) 1995-03-08 1995-03-08 Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant

Publications (2)

Publication Number Publication Date
ES2150107T3 true ES2150107T3 (es) 2000-11-16
ES2150107T5 ES2150107T5 (es) 2009-08-05

Family

ID=9476864

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96906795T Expired - Lifetime ES2150107T5 (es) 1995-03-08 1996-03-07 Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.

Country Status (6)

Country Link
KR (1) KR100309856B1 (es)
CN (1) CN1226046C (es)
ES (1) ES2150107T5 (es)
FR (1) FR2731355B1 (es)
OA (1) OA10615A (es)
PT (1) PT814834E (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE465754T1 (de) * 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
FR2844514B1 (fr) * 2002-09-16 2007-10-19 Neovacs Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
AU2014359085B2 (en) * 2013-12-08 2017-11-02 Peptcell Limited HIV antigens and antibodies and compositions, methods and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins
WO1991015224A1 (en) * 1990-03-30 1991-10-17 Smithkline Beecham Corporation Inhibition of disease associated with immunodeficiency virus infection
WO1991018454A1 (en) * 1990-05-18 1991-11-28 Centre National De La Recherche Scientifique Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
JPH06508603A (ja) * 1991-02-14 1994-09-29 ラ　ホヤ　キャンサー　リサーチ　ファウンデーション ＨＩＶ　Ｔａｔタンパク質に対する新規インテグリン特異性
ATE245661T1 (de) * 1992-04-24 2003-08-15 Inst Human Genetics Biochem Natürliche menschliche igm antikörper
WO1993025235A1 (en) * 1992-06-09 1993-12-23 President And Fellows Of Harvard College Aids therapeutics based on hiv-2 vpx peptides
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
FR2700169B1 (fr) * 1993-01-04 1995-03-24 Transgene Sa Nouveaux variants trans-dominants TAT du virus de l'immunodéficience humaine.
WO1995004546A1 (en) * 1993-08-06 1995-02-16 Kai Juhani Ernst Krohn Novel mutated human and simian immunodeficiency viruses and vaccines containing said viruses

Also Published As

Publication number Publication date
FR2731355A1 (fr) 1996-09-13
KR19980702834A (ko) 1998-08-05
CN1181020A (zh) 1998-05-06
FR2731355B1 (fr) 1997-05-30
KR100309856B1 (ko) 2003-03-06
CN1226046C (zh) 2005-11-09
OA10615A (fr) 2002-08-30
ES2150107T5 (es) 2009-08-05
PT814834E (pt) 2001-01-31

Similar Documents

Publication Publication Date Title
EE03969B1 (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
PT750618E (pt) Derivados de oxazolidinona e composicoes farmaceuticas que os contem
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
DK0813525T3 (da) Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
ES2142798T3 (es) Derivados de 3-amido pirazol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
TR200101822T2 (tr) Kontrollü salınan galantamin bileşimi
FI931708A0 (fi) Herbicida substituerade aryl-haloalkylpyrazoler
FI913478A0 (fi) Diazinderivat.
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
ES2051641B1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
ES2126966T3 (es) Proceso para la impregnacion hidrofuga de yeso.
CO4180420A1 (es) Nuevos derivados de 3-arilpirazoles, sus procedimientos de preparacion, composiciones que les contienen y su utiliza- cion contra las enfermedades fungicas
BR9708114A (pt) Análogos xantona para o tratamento de doenças infecciosas.
MY137184A (en) Dibenzoylalkylcyanohydrazines.
ES521422A0 (es) Procedimiento para la obtencion de derivados de carboxilamida n-glicosilados.
DK0814834T4 (da) Immunogener, der er blottet for toksicitet, afledt af et retroviralt regulatorprotein, antistoffer, der er rettet mod disse immunogener, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
EA200000431A3 (ru) Новые замещенные димерные соединения, способ их получения и фармацевтические композиции, содержащие их
ES8609312A1 (es) Procedimiento para la preparacion de silibinina exenta de isosilibina
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
ES2066546T3 (es) Composicion farmaceutica para inhibir la resorcion osea.
ES2150107T3 (es) Inmunogenos no toxicos que proceden de una proteina de regulacion retroviral, anticuerpos dirigidos contra estos inmunogenos, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2177535T3 (es) Vacunas contra protozoos intestinales.
DE69111607D1 (de) Reine kristalline form von rifapentin.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 814834

Country of ref document: ES